Clamovid

Clamovid is a combination antibiotic product containing amoxicillin and clavulanic acid, developed and marketed by the Malaysian pharmaceutical company Hovid. Amoxicillin is a semi-synthetic, broad-spectrum penicillin-class antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Clavulanic acid is a beta-lactamase inhibitor that irreversibly binds to and inactivates beta-lactamase enzymes, which are produced by resistant bacteria to degrade beta-lactam antibiotics. By combining these two agents, Clamovid effectively extends the antibacterial spectrum of amoxicillin to include many organisms normally resistant to amoxicillin and other beta-lactam antibiotics. It is indicated for the treatment of various bacterial infections, including sinusitis, otitis media, respiratory tract infections, urinary tract infections, and skin and soft tissue infections.

Brand names

Clamovid

Other names

amoxicillin + clavulanic acidco-amoxiclav